SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 4 — Focused Visit (Follow-up) — Alan Turing — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientAlan Turing
Date of birth1912-06-23
IdentifiersMRN HR-ML007-SYN-TD; SSN (made up) 000-07-6290
Document date1953-08-04
AuthorRupert Hallam, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Sixteen-week review of hormone recovery and depression treatment. [S]

History of Present Illness

Mr. Turing returns eight weeks after starting bupropion XL 150 mg. The nurse telephone check planned for two weeks after the start did not happen: he was abroad at a conference, two calls went unanswered, and no further call was booked. He had a dry mouth and some difficulty falling asleep in the first week, which settled when he took the tablet earlier in the morning, and no headache, tremor, or restlessness. He has missed no doses. His mood is clearly better: he enjoys running again, at about 35 km a week, and has started working on a new problem with real pleasure. He sleeps about seven hours. Libido and erections are back to his usual. He has had fourteen psychotherapy sessions. The breast tissue is smaller and tender only when pressed. He has had no suicidal thoughts. [S]

ElementDetail
Missed contactTwo-week nurse call after starting bupropion not completed
BupropionDry mouth and trouble falling asleep in week one, now settled; no missed doses
Sexual functionLibido and erections back to his usual
RunningAbout 35 km a week
SafetyNo suicidal thoughts
PHQ-97, down from 15

Review of Systems

SystemResultFinding
BreastNegativeTender only when pressed; no discharge
NeurologicalNegativeNo headache, tremor, or seizures
CardiovascularNegativeNo palpitations
PsychiatricPositiveMild residual low mood on some days; no suicidal thoughts, elevated mood, or racing thoughts

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Cholecalciferol 1,000 units (25 mcg) oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1953-04-14activeS
Bupropion extended-release 150 mg oral tablet, one tablet by mouth each morningOne tablet by mouth each morningOral route1953-06-09activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1953-08-04Body height178cmS
1953-08-04Body weight69.3kgS
1953-08-04Body mass index (BMI) [Ratio]21.9kg/m2S
1953-08-04Systolic blood pressure124mm[Hg]S
1953-08-04Diastolic blood pressure78mm[Hg]S
1953-08-04Heart rate60/minS
1953-08-04Respiratory rate14/minS
1953-08-04Body temperature36.7CelS
1953-08-04Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1953-08-04Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]7{score}S
1953-08-04Testosterone [Mass/volume] in Serum or Plasma452ng/dL264-916 ng/dLNormalS
1953-08-04Lutropin [Units/volume] in Serum or Plasma4.8m[IU]/mL1.7-8.6 m[IU]/mLNormalS
1953-08-04Follitropin [Units/volume] in Serum or Plasma5.2m[IU]/mL1.5-12.4 m[IU]/mLNormalS
1953-08-04Hemoglobin [Mass/volume] in Blood14.4g/dL13.2-16.6 g/dLNormalS

Physical Exam

Vital signs recorded on 1953-08-04; see the Vital Signs section. [S]

SystemFinding
GeneralWell; brisk
BreastExamined with his agreement: glandular tissue about 2.5 cm behind the left nipple and 1.5 cm behind the right, tender only on firm pressure; no discrete mass
Mental statusAlert; mood "much more like myself"; affect reactive with humor; thought process linear; no suicidal ideation; insight and judgment good

Problems

ProblemClinical statusVerificationCodeProvenance
Bilateral gynecomastia, tender, about 4 cm of firm glandular tissue behind each nipple, after a year of high-dose estrogen; synthetic modern diagnosis linked to the documented breast growth from his hormone treatmentactiveconfirmed N62S — Synthetic modern diagnosis. That the hormone treatment caused breast growth is reported in the sources (D, mentioned once in his own words); the examination findings are synthetic.
Suppressed testosterone and gonadotropins from exogenous estrogen (drug-induced hypogonadotropic hypogonadism), with low libido, erectile difficulty, and fatigueresolvedconfirmed E23.1S — Synthetic consequence of high-dose estrogen, which suppresses LH and FSH; recovery is expected once it stops.
Adverse effects of high-dose estrogen given for a year without free and informed consent, as the alternative to imprisonmentactiveconfirmed T38.5X5AS — Synthetic modern framing of the documented hormone treatment imposed after his conviction (D); in the modern episode it is recorded as iatrogenic harm.
Major depressive disorder, single episode, moderate, after prosecution and coerced hormone treatment; synthetic modern diagnosis (no depression diagnosis is documented in his lifetime)activeconfirmed F32.1S — Synthetic modern diagnosis. That he sought Jungian analysis after the trial is documented (D); calling his state then a depressive illness is a retrospective interpretation (R).
Vitamin D insufficiency (25-hydroxyvitamin D 22 ng/mL)activeconfirmed E55.9S — Synthetic finding of the bone-health workup.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationBreast examination for size, tenderness, and any discrete massEvery visit until the gynecomastia settlesCompleted todayGlandular tissue about 2.5 cm on the left and 1.5 cm on the right, tender only on firm pressure; no discrete mass
LaboratoryTestosterone, LH, and FSHEvery 6 to 8 weeks after the exposure stops, until normalCompleted todayTestosterone 452 ng/dL, LH 4.8 and FSH 5.2 mIU/mL: all normal; recovery complete
LaboratoryHemoglobin while testosterone is lowWith each hormone check until normalCompleted today14.4 g/dL
ImagingBone density (DXA)If hypogonadism persists beyond six months or a fragility fracture occursNot indicatedThe axis recovered within about four months of the last estrogen dose
Medication safetyTestosterone therapyOnly for persistent, symptomatic, confirmed testosterone deficiencyNot indicatedNot given while the axis recovers: it would suppress LH and FSH again and is not indicated for a transient, drug-induced low testosterone
SurveyPHQ-9Baseline, then at least monthly during acute treatment; every 2 to 4 weeks in continuationCompleted today7, down 53 percent from 15: response; remission not yet reached
SurveySuicide risk reassessment (C-SSRS Since Last Visit and PHQ-9 item 9)Every visit during active treatmentCompleted todayNo suicidal thoughts, intent, plan, or behavior since the last visit; PHQ-9 item 9 scored 0. Safety plan reviewed
Medication safetyAntidepressant tolerability check two weeks after starting2 weeks after starting and after each dose changeDeferredNot done, a deviation from the protocol: the nurse telephone check two weeks after bupropion was started, which was also to supply the monthly PHQ-9, was not completed after two unanswered calls while he was abroad, and no further call was booked, leaving eight weeks without a score. No harm resulted judging by today's review: the early insomnia and dry mouth settled, blood pressure is 124/78 mmHg, and there were no suicidal thoughts. Corrective action: a missed safety call is now rebooked within two days and flagged to Dr. Hallam if it cannot be completed
Medication safetyAdherence, adverse effects, and blood pressure on bupropionEvery visit during active treatmentCompleted todayNo missed doses; early dry mouth and insomnia settled; blood pressure 124/78 mmHg
Self-managementPsychotherapy, sleep, running, and social contactEvery visit during active treatmentCompleted todayFourteen sessions; sleep about seven hours; running about 35 km a week
LaboratoryLithium, anticonvulsant, or antipsychotic monitoring (levels, metabolic tests, AIMS)Only on those drugsNot indicatedNot on any of these drugs

Goal progress:

Guideline basis: EAA clinical practice guidelines: gynecomastia evaluation and management (2019); Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline (2018); Osteoporosis in Men: An Endocrine Society Clinical Practice Guideline (2012); VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)

Follow-up: Six-month review in two months with testosterone, estradiol, vitamin D, and PHQ-9. Next scheduled visit 1953-10-06: six-month review of gynecomastia and depression in continuation treatment. [S]